

SUBJECT INDEX TO VOLUME 4

<i>N</i> -Acetyl-D-penicillamine.....	16	pyloricidin derivatives as.....	203
as chelating agent.....	16	pyrazoles as.....	204
Acetylcholine receptor.....	578	γ -pyrone derivatives as.....	203
immunotoxins for.....	578	quinolone compound as.....	203
Acute myelogenous leukemia (AML).....	255	Anti-lymphocytes.....	572
genetic abnormalities in.....	255	immunotoxins of.....	572
targeting FLT3 receptor tyrosine kinase in.....	255	Anti-protozoa agent.....	31
<i>S</i> -Acyl-2-thioethyl (SATE) pronucleotides.....	395	semicarbazones as.....	31
antiviral activity of.....	395	Antibacterial.....	441
diesters of.....	404	sugar containing agents.....	441
mononucleoside mixed.....	401	Antibacterial activity.....	72
toxicity of.....	400	of β -lactam derivatives.....	72
Adefovir dipivoxil (hepsera TM).....	207	of lysophospholipid analogues (LPAs).....	142,143
as new drug.....	207	Anticancer agents.....	1077
Alfuzosin hydrochloride.....	1107	ampethinile as.....	1088
synthesis of.....	1107	aromatic carbamets as.....	1087
Alzheimer's disease (AD).....	157	aryl-naphthyridinones as.....	1091
caspase enzyme in.....	157	benzothiophene compounds as.....	1092
Amine-carboxyboranes.....	1001	benzoylureas as.....	1091
activities of.....	1013	chalcones as.....	1087
derivatives of.....	1001	chelerythrine as.....	1090
medicinal chemistry of.....	1001	chelidonine as.....	1090
recent advances in.....	1001	chloroethylurea (CEU) as.....	1092
α -Aminoboronic acids.....	1001	colchicine/analogues as.....	1083
derivatives of.....	1001	combretastatins as.....	1085
medicinal chemistry of.....	1001	cryptophysin analogues as.....	1095
recent advances in.....	1001	curacin A as.....	1088
Aminopenicillins.....	106	development of.....	1077
as β -lactam.....	106	diethylstilbsterol as.....	1089
Aminopyrazine derivatives.....	421	5,6-dihydroindolo[2,1-A]isoquinoline	
as antioxidants.....	421	derivatives as.....	1091
chemical reactivity assays of.....	425	dolastatin/derivatives as.....	1095
LDL protection inhibition by.....	428	flavonols as.....	1086
lipid peroxidation inhibition by.....	425	FR 182877 as.....	1098
theoretical evaluation of.....	424	hemistarlins as.....	1098
toxicity of.....	429	indanosine as.....	1092
Amrubicin hydrochloride (calsed).....	207	IKP-as.....	1095
as new drug.....	207	KAR derivatives as.....	1095
Amyotrophic lateral sclerosis.....	139	LY290181 as.....	1092
dihydro-4-oxo-4H-imidazo[1,2-a]indeno		MAPs as.....	1098
[1,2-e] pyrazineseries in.....	139	motor proteins as target for.....	1098
Angiogenesis.....	693	nocodazole as.....	1092
heparanase in.....	693	paclitaxel site binding drug as target of.....	1081
Anthraquinone derivative.....	203	phenyl-4-quinolones (PQ) as.....	1090
as anti- <i>helicobacter pylori</i>	203	phomopsin A as.....	1097
Anti- <i>Helicobacter pylori</i>	201	pironetin/derivatives as.....	1096
anthraquinone derivatives as.....	203	podophyllotoxin/analogues as.....	1084
arylacetamides as.....	204	quinolones/derivatives as.....	1090
benzimidazoles as.....	204	rotenone as.....	1090
cephem derivative as.....	203	RPR112378 as.....	1093
clinically useful drugs in.....	201	RPR115781 as.....	1093
guanidino agents as.....	201	sanguinarine as.....	1090
phthalide derivatives as.....	203	steganacin as.....	1088
		spongistatin as.....	1096
		sulfonamides as.....	1089
		target for.....	1077
		1,2,3,4-tetrahydro-2-phenyl-quinones as.....	1090

- tricyclic pyron anlog (TP) as 1093
 tryprostatins as 1099
 vinca alkaloid site binding drugs as target for 1094
 vindesine as 1094
- Anticancer titanium compounds 49
 antitumor activity of 49
 biological transport of 50
 bis(4-acyl-5-pyrazolon-5-ato)titanium conformers as 57
 budotitane as 49
 formulation of 50
 interaction with 51
 structural parameters of 57
 titanocene dichloride as 50
- Anticonvulsant 31
 semicarbazones as 31
- Anticonvulsant activity 126,137
 of dihydro-4-oxo-4H-imidazo[1,2-a]indeno
 [1,2-e] pyrazine series in 126,137
- Antimicrobial activity 32
 of thiosemicarbazones 32
- Antimicrobial agents 73
 β -lactam derivatives as 73
- Antioxidants 421
 aminopyrazine derivatives as 421
- Antiprotozoal activity 141
 of lysophospholipid analogues (LPAs) 141
- Antitubercular compounds 74
 β -lactam derivatives as 74
- Antitumor activity 33,49,630
 of anticancer titanium compounds 49
 of dual COX-2/carbonic anhydrase inhibitors 630
 of thiosemicarbazones 33
- Antiviral activities 395,446
 of sugar containing agents 446
 of *S*-acyl-2-thioethyl (SATE) pronucleotides 395
- Antiviral protein 526
 pokeweed as 526
- Apoptosis 882
 genistein in 882
- Aprepitant 1108
 synthesis of 1108
- Arginine 823
 catabolism of 824
 cellular effects of 823
 effects of 825
 effect on cardiovascular system 825
 effect on carcinogenesis/tumor growth 829
 effects on endocrine system 830
 effects on immune system 827
 effect on nitrogen balance 830
 metabolic pathways of 824
 NO-independent effects of 826
 other NO-dependent effects of 825
 physiological effects of 823
 role in wound healing 828
- Aripiprazole (abilifyTM) 207
 as new drug 207
- Artificial neural network methods 167
 water solubility QSPR Models generated by 167
- Arylacetamides 204
 as anti-*helicobacter pylori* 204
- Aryloxy phosphoramidate triesters 371
 applications of 374
 application to acyclic nucleoside phosphonates 375
 as protides 371
 mechanism of action of 378
 of AZT 372
 SARs of 376
- Arylureas 326
 as 5-HT_{2B} antagonist 326
- Atazanavir sulfate 1109
 synthesis of 1109
- Atomoxetine hydrochloride 1110
 synthesis of 1110
- Autoimmunity therapy 742
 mycophenolic acid in 742
- Axonal retrograde transport 519
 of ribosome inactivating proteins (RIP) 519
- Azelnidipine 1111
 synthesis of 1111
- AZT 372
 aryloxy phosphoramidate triesters of 372
- Bacteria 461
 ribosome-inactivating proteins (RIP) in 461
- Benzimidazoles 204
 as anti-*helicobacter pylori* 204
- Bioactive carbohydrates 437
 analogues of 437
 as chemotherapeutics 437
 in influenza 440
 in malaria 439
 in tuberculosis 438
- Biological activity 881
 of soy flavonoids 881
- Biological adhesives 185
 poly- α -glutamic acid as 185
- Bis(4-acyl-5-pyrazolon-5-ato)titanium conformers 57
 as anticancer titanium compounds 57
- Bispecific antibodies 573
 immunotoxins with 573
- Bladder cancer 61,66
 copper-67 in treatment of 66
 diagnosis of 61
 rhenium-188 in treatment of 66
 therapy of 61
- Bortezomib 1111
 synthesis of 1111

- Butyrate.....840
cellular/physiological effects of.....840
- Cancer.....843,882
short chain fatty acids (SCFC) in.....843
genistein in.....882
- Cancer therapy.....273
receptor protein tyrosine kinases (RPTKs) in.....273
- Carbapenems.....81
biological activity of.....81
synthesis of.....81
- Carbonic anhydrases.....628
inhibition by sulfonamides.....628,629
- Cardiac disease.....155
caspase enzyme in.....155
- Cardiovascular system.....825
effects of arginine on.....825
- Carrier molecules.....545
antibodies as.....546
cytokines/growth factors as.....547
harmones as.....547
RIP as.....547
- Caspase enzyme.....153
apoptotic inhibition of.....163
in Alzheimer's disease.....157
in cardiac disease.....155
in drug design.....158
in Huntington's disease.....157
in liver failure.....157
in neurodegeneration.....157
in Parkinson's disease.....157
in rheumatoid arthritis.....155
in sepsis.....156
in spinal cord injury.....156
in stroke.....155
in traumatic brain injury.....156
indications of.....154
inhibitors of.....153,161
- CCK receptor ligands.....670,677
of dipeptides.....670,677
- Cellular signaling networks.....319
in phosphoproteomics.....319
- Cellular/physiological effects.....833,881
of glutamine.....833
of soy flavonoids.....881
- Cephalosporins.....93
as β -lactams.....93
- Cephem derivative.....203
as anti-*helicobacter pylori*.....203
- Cephems.....105
as β -lactams.....105
- Cereal ribosome-inactivating proteins.....493
activities of.....499
as defence strategy in transgenic plants.....500
genetics of.....493
- properties of.....493
ribosomes resistant to.....498
- Chelating agents.....15
clinically important.....14
chemical structures of.....11
desferrioxamine (DFOA) as.....12,16
diethylenetriaminepentaacetic acid (DTPA) as.....12,16
D,L-2,3-dimercapto-1-propanesulfonic acid (DMPS) as.....11,16
2,3-dimercaptopropanol (BAL) as.....12
ethylenediaminetetraacetic acid (EDTA) as.....11,16
in vivo efficacy of.....15
N-acetyl-D-penicillamine (NAPA) as.....16
toxicity of.....15
- Chemical chelation.....11
effects on metal toxicity.....12
in biological systems.....14
in treatment of metal intoxications.....11
- Chemogenomics.....235
computational tools for.....240
data management in.....243
example of.....246
gene family-based approach to.....235
high-throughput screening in.....241
hit confirmation in.....242
in structure-based drug design.....235
inhibitor-based ATP site homology in.....244
of kinases.....236,239
scaffold morphing in.....246
selectivity profiling in.....243
structural basis for.....236
target hopping in.....246
- Chlorophenyl piperazine 6 (m-CPP).....327
as 5-HT_{2B} antagonist.....327
- Chronic myelogenous leukemia.....285
Bcr-Abl in intracellular signaling of.....286
imatinib (STI571) resistance in.....285,291,296
Philadelphia chromosome in.....285
- Colon anastomosis repair.....773
MMP inhibition in.....775
- Colorectal carcinoma.....772
epidemiology of.....772
- Combinatorial chemistry.....1067
- Computational techniques.....1029
application of.....1036
clustering/decision tree techniques as.....1033
for compound classification.....1029
for diversity analysis.....1029
in compound classification.....1036
in diversity analysis.....1036
in virtual screening.....1037
metrics in.....1031
neural networks in.....1034
partitioning/cell-based methods as.....1034
QSAR.....1033
- Copper-67.....64
applications/biological effectiveness of.....64
biological fate of.....65

- clinical applications of 65
in treatment of bladder cancer 66
radiochemistry of 64
structure of 65
- COX-2 inhibition 603
enzyme kinetics of 605
structural approach for 603,606
- COX-2 inhibitors 617,629
allergy to 624
clinically used-1 625
gastrointestinal safety of 619
of COXIB type 625
pharmacodynamics of 617
pharmacokinetics of 618
second generation of 617
therapeutic efficacy of 618
- COX-2 selective inhibitors 597
first generation of 597
second generation of 599
- Cyclooxygenase pathways 633
- Cyclooxygenases 604
COX binding site of 604
structure of 604
- Cytokines/growth factors 547
as carrier molecules 547
- Cytomegalovirus 527
pokeweed antiviral protein (PAP) for 527
- Decision support systems (DSS) 1019
challenges in 1024
chemical structure processing in 1025
client/sever in 1021
clustering in 1026
currently used 1020
desktop and 1023
in drug discovery 1019
models in 1026
technology in 1024
web-based 1020
- Desferrioxamine (DFOA) 12,16
as chelating agent 12,16
- Dexmethylphenidate hydrochloride FocalinTM 210
as new drug 210
- Diethylenetriaminepentaacetic acid (DTPA) 12,16
as chelating agent 12,16
- Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazine series 123
anticonvulsant activity of 126,137
chemical structure of 123,124
duration of action of 132
in amyotrophic lateral sclerosis 139
in ischemia-induced brain damage 139
in spinal cord function 139
in trauma-induced brain alteration 139
in vivo activities of 124
in vitro binding studies of 134
LY300164 as 123
- LY293558 as 123
- NBQX as 123
- NPQX as 123
- 8- or/ and 9-substituted-4-oxo-imidazo[1,2-a]indeno [1,2-e]pyrazine derivatives as 131
- RPR 117824 as 139
- RPR119990 as 139
- structure-activity relationships (SAR) of 134
- YM872 as 123
- D,L-2,3-Dimercapto-1-propanesulfonic acid (DMPS) 11,16
as chelating agent 11,16
- 2,3-Dimercaptopropanol (BAL) 12
as chelating agent 12
- Dipeptoids 669
CCK receptor ligands of 670,677
conformationally constrained analogues of 673
pharmacokinetic profile of 672
structure activity relationships of 670
to design peptidomimetics 669
- Diversity analysis 1029
application of 1036
descriptor's in 1029
dissimilarity and 1032
methods of 1032
metrics in 1031
- Drug carrier 183
poly- α -glutamic acid as 183
- Dual acting antihistaminergic agents 923
dual acting bradykinin B₂ as 928
dual acting leukotriene modifying agents-H₁ receptor antagonists 923
dual acting tachykinin/histamine H₁ receptor antagonists as 927
dual histamine H₁-H₂ receptor antagonists as 929,930
dual histamine H₁-H₄ receptor antagonists as 930
dual histamine H₁ receptor antagonist-thromboxane A₂ receptor antagonist as 923
dual histamine H₁ receptor-PAF antagonists as 930
- Dual COX-2/carbonic anhydrase inhibitors 630
antitumor activities of 630
- Dual COX/5-LOX inhibitors 633
fenamate derivatives as 635
indomethacin derivatives as 634
pharmacophores combination in 635
pyrrolizine derivative as 636
- Dutasteride (avodartTM) 212
as new drug 212
- Emcitritabine 1112
synthesis of 1112
- Enteric-coated capsules 41
containing insulinomimetic vanadyl compounds 41
trials for 47
- Epidermal growth factor receptor (EGF) kinase inhibitors of 273

Epinastine	1113	chemical functionalization of	805
synthesis of	1113	synthesis of	805
Ertapenem sodium (invez TM)	212	Fulvestrant (faslodex [®])	218
as new drug	212	as new drug	218
Escitalopram oxalate (cipralex [®])	213	Fungal viruses	530
as new drug	213	pokeweed antiviral protein (PAP) for	530
Ethylenediaminetetraacetic acid (EDTA)	11,16	Fungi	461
as chelating agent	11,16	ribosome-inactivating proteins (RIP) in	461
Etoricoxib (arcoxia TM)	213	GABA _A -benzodiazepine receptor (BZR)	909
as new drug	213	development of radioligands for	909
Eukaryotic protein kinases	301	<i>in vivo</i> imaging of	909
architecture of	301	molecular biology/pharmacology of	910
superfamily of	301	radiolabelled ligands for	910
Everolimus	1114	<i>Ganoderma lucidum</i> (Reishi)	873
synthesis of	1114	cellular/physiological effects of	873
Extracellular trypanosomatids	146	future directions of	878
effects on lysophospholipid analogues (LPAs)	146	<i>in vitro</i> effects of polysaccharides from	874,875
Ezetimibe (zetia)	214	<i>in vitro</i> effects of triterpenes from	876,877
as new drug	214	other biologically active components of	877
ω3 Fatty acids	659	Gastrointestinal absorption features	44
analogues of	659	of vanadyl compounds	44
effect on arachidonic cascade	659	Gastrointestinal stromal tumors (GISTs)	279
metabolism of	660	kinase inhibitors in	279
sources of	659	Gefitinib (iressa)	218
therapeutic benefits of	659	as new drug	218
Ferrocene-chloroquine derivatives	27	Gemifloxacin mesylate	1116
for malaria	27	synthesis of	1116
FLT3 kinase	255	Gene expression	497
animal models of	258	of maize ribosome-inactivating proteins	497
biological activities of mutant	260	Genistein	882
deficiency of	258	effects on cardiovascular system	884
molecular mechanisms of	261	in apoptosis	882
role in AML	259	in cardiovascular disease	884
FLT3 receptor tyrosine kinase	255	in cancer	882
in acute myelogenous leukemia (AML)	255	in regulation of cell cycle	882
FLT3 TKI inhibitors	261	in osteoporosis	885
chemical structures of	263	Glutamine	833
pre-clinical profiles of	261,264	as fuel	836
quinazoline compounds as	267	as growth promoting agent	836
Fondaparinux sodium (arixtra TM)	215	as neurotransmitter	835
as new drug	215	catabolism of	833
Fosamprenavir calcium	1115	cellular/physiological effects of	833
synthesis of	1115	regulates renal acid-base homeostasis	835
Fosfluconazole	1115	regulation of	833
synthesis of	1115	role in critical illness	836
Frovatriptan succinate (frova TM)	218	Glycoprotein IIb/IIIa receptor	703
as new drug	218	inhibition of	704
Fuel	836	inhibitors of	703
glutamine as	836	GP IIb/IIIa inhibitors	707
Fullerene-containing amino acids	805	Growth factor receptors	573
biological properties of	805	immunotoxins for	573
		Growth promoting agent	836
		glutamine as	836

- Guanidino agent201
 as anti-*helicobacter pylori*.....201
- Heparanase.....693
 in angiogenesis.....693
 in inflammation.....693
 inhibitors of.....699
 in tumour metastasis.....693
 transition state analogues of.....699
- Heparin.....693
 mimetic polymers.....695
- Herpes simplex virus.....527
 pokeweed antiviral protein (PAP) for.....527
- Herpes virus proteases (HCMV,HSV) inhibitor.....193
 sulfonamide derivatives as.....193
- Histamine derivatives.....935
 as histamine H₁-receptor agonists.....935
- Histamine H₁-receptor agonists.....935
 histamine derivatives as.....935
 histaprodifen as.....936,937
 methylhistaprodifen as.....936
 SAR of.....935
- Histamine H₂-receptor agonists.....941
 amines as.....943
 guanidines as.....643
 QSAR of.....945
 SAR of.....941
 species-selectivity of.....947
- Histamine H₂-receptor antagonists.....949
 compounds from.....949
 pharmacological properties of.....951
- 5-HT_{2B} antagonists.....325
 arylureas as.....326
 indolonaphthyridines as.....327
meta-chlorophenyl piperazine 6 (m-CPP) as.....327
 pyrimidines as.....327
 rylpiperazine scaffold as.....327
 tetrahydro- β -carboline as.....328
- Histamine H₂-receptor ligands.....941
 QSAR of.....945
 SAR of.....941
- Histamine H₃ receptor agonists.....949
 imetit derivatives as.....960
 imifuramine as.....961
 immepip derivatives as.....960
 impentamine derivatives as.....961
 ligands for.....955
 SAR of.....955
 stereoisomer of.....961
 targets of.....955
- Histamine H₃ receptor antagonists.....965
 affinities of.....970
 and hybrid compounds.....974
 and radioligands.....974
 indication for.....969
 in human tissues.....968
 medicinal/chemical aspects of.....965
- molecular modeling studies of.....971
 neutral antagonists of.....973
 partial agonists of.....973
 pharmacological aspects of.....965
 potencies of.....970
 QSAR of.....971
- Histamine H₄ receptor.....993
 ligands of.....993
 therapeutic uses of.....993
- 5-HT_{2B} Receptor.....325
 subtypes of.....325
- Histaprodifen.....936,937
 as histamine H₁-receptor agonists.....936,937
- HIV entry inhibitor.....198
 sulfonamide derivatives as.....198
- HIV integrase inhibitor.....195
 sulfonamide derivatives as.....195
- HIV protease inhibitor.....190
 sulfonamide derivatives as.....190
- Homology-based modelling.....793
 alignment in.....794
 database screening in.....799
de novo ligand design in.....800
 in drug design.....797
 model building in.....794
 targets for rational drug design.....793
 template identification in.....794
- Human immunodeficiency virus (HIV).....528
 pokeweed antiviral protein (PAP) for.....528
- Human thymidylate kinase (TMPK).....351
 engineering of.....360
 nucleotide analogs phosphorylation by.....351
 nucleotide specificity of.....352
 substrate specificity of.....352
- Huntington's disease.....157
 caspase enzyme in.....157
- Ibandronate sodium.....1116
 synthesis of.....1116
- Imatinib mesylate (STI571).....288
 as kinase inhibitor.....288
- Imetit derivatives.....960
 as histamine H₃ receptor agonist.....960
- Imidazolylpropylguanidines.....945
 molecular modeling of.....949
- Imifuramine.....961
 as histamine H₃ receptor agonist.....961
- Immepip derivatives.....960
 as histamine H₃ receptor agonist.....960
- Immobilized metal affinity chromatography.....313
 of phosphoproteomics.....313
- Immune function.....850
 effects of medium-chain triglycerides (MCT) on.....850

Immune system.....	827	of epidermal growth factor receptor (EGF).....	273
effects of arginine on.....	827	of FLT3	280
Immunomodulating activity.....	518	of kinase receptor	279
of ribosome inactivating proteins (RIP).....	518	of vascular endothelial growth factor (VEGF).....	277
Immunomodulation.....	143	reversible.....	273
lysophospholipid analogues (LPAs) in.....	143	STI571 as.....	288
Immunotoxins.....	545	β -Lactams.....	93
as conjugates.....	545	biological activity of.....	93
characteristics of.....	545	cephalosporins as.....	93
cocktails of anti-lymphocytes	572	cephems as.....	105
cytotoxicity of.....	554	oxacephems as.....	105
in neuroscience research.....	588	prodrugs (antibacterial/anticancer) of.....	103
non-covalent.....	552	synthesis of.....	93
potency of.....	554,557	β -Lactam derivatives.....	69
preparation of.....	545,548,557	antibacterial activity of.....	72
pre-clinical studies of.....	563	as antitubercular compounds.....	74
recombinant/fusion.....	552	as antimicrobial agents	73
systemic injections of.....	586	biological activity of.....	69
targeting acetylcholine receptor	578	monocyclic	73
targeting haematological cells.....	563	LDL protection inhibition	428
targeting growth factor receptors.....	573	by aminopyrazine derivatives.....	428
targeting solid tumour antigens.....	576	Leishmaniasis	28,146
to HIV-infected cells.....	577	lysophospholipid analogues (LPAs) in.....	146
with bispecific antibodies	573	Library design.....	1067
Immunotoxins.....	585	and library optimisation algorithms.....	1069
neuropeptide-toxin conjugates of.....	585	and optimisation.....	1067
Impentamine derivatives.....	961	docking methods for.....	1074
as histamine H ₃ receptor agonist.....	961	frequency based methods of.....	1069
Indolonaphthyridines	327	methods for.....	1067
as 5-HT _{2B} antagonist	327	multi-objective methods for	1072
Indolylpiperazines	998	pre-requisites of.....	1068
H ₄ receptor affinity of.....	998	products verses reactant based design as	1067
Inducible nitric oxide synthase	741	reactant selection methods in.....	1071
cell-specific inhibition of	744	stochastic methods of.....	1070
inhibition by mycophenolic acid	741	Library optimisation algorithms	1069
Inflammation	693	and library design.....	1069
heparanase in.....	693	Lipid peroxidation inhibition.....	425
short chain fatty acids (SCFA) in.....	841	by aminopyrazine derivatives.....	425
Influenza	440	Lipoxygenase.....	633
bioactive carbohydrates in.....	440	Liver failure.....	157
Influenza virus.....	527	caspase enzyme in	157
pokeweed antiviral protein (PAP) for	527	Lock-in <i>cyclosal</i> -pronucleotides	383
Insulinomimetic vanadyl compounds.....	41	as chemical trojan horses	383
enteric-coated capsules containing	41	antiviral evaluation of	390
Ischemia-induced brain damage.....	139	chemistry of.....	390
dihydro-4-oxo-4H-imidazo[1,2-a]indeno		properties of.....	390
[1,2-e] pyrazineseries in.....	139	Lumiracoxib	1117
Isoxazole-based dual p38/JNK3 inhibitors	250	synthesis of.....	1117
structures of.....	250	Lysophospholipid analogues (LPAs).....	141
Kinase inhibitor.....	273,288	anticancer activities of.....	142,143
imatinib mesylate (STI571) as.....	288	antiprotozoal activities of.....	141
in gastrointestinal stromal tumors (GISTs).....	279	clinical studies of.....	142
inhibit tumor angiogenesis.....	277	chemical structures of.....	143
irreversible.....	273	effects on extracellular trypanosomatids.....	146
		effects on mammalian tumor cells	148
		in immunomodulation	143

- in leishmaniasis.....146
mechanisms of action of.....145
- Maize ribosome-inactivating proteins.....495
biological role of.....497
features of.....495
gene expression of.....497
identifications of.....495
toxicity of.....497
- Malaria 25,439
bioactive carbohydrates in.....439
ferrocene-chloroquine derivatives for 27
N₂O₂ core complexes for 28
pentamidine for.....28
porphyrins for.....28
- Matrix metalloproteinases 769
in colon anastomosis repair 769,773
in physiology 772
inhibitors of 772
- Medium-chain triglycerides (MCT)847
and infectious complications850
cellular/physiological effects of.....847
clinical studies of.....850
effects on cellular membrane function.....853
effect on gene-transcription.....854
effects on immune function.....850
effects on intracellular signal transduction.....854
effects on mononuclear cell/reticulo-endothelial system function852
effect on monocyte/reticulo-endothelial system function.....852
effects on neutrophil function850
effects on neutrophil adhesion.....851
effects on neutrophil migration851
effects on lymphocyte function852
effects on production of lipid mediators.....854
lipid structure of847
metabolic effects847
neutrophil microbial killing capacity of.....852
oxygen radical production of852
- Memantine 1117
synthesis of.....1117
- Metal complexes..... 25
in trypanosomiasis 25
- Metal complexes..... 31
of semicarbazones..... 31
- Metal toxicity 12
effect of chemical chelation on..... 12
- Methylhistaprodifen936
as histamine H₁-receptor agonist936
- Microtubules (MTs) 1077
as target for developing anticancer drug 1079
binding sites of.....1077
classification of inhibitors of.....1079
components of.....1077
dynamics of.....1078
function of.....1078
in cell division1078
- isotypes of..... 1078
role of..... 1078
- Miglustat 1118
synthesis of..... 1118
- MMP inhibition..... 775
in colon anastomosis repair..... 775
- Molecular descriptors..... 1031
classes of..... 1031
- Molecular similarity 1029
application of 1036
descriptors in..... 1029
methods of..... 1032
metrics in 1031
neural networks in..... 1034
- MT inhibitors 1079
ampethinile as 1088
aromatic carbamets as..... 1087
aryl-naphthyridinones as..... 1091
benzothiophene compounds as 1092
benzoylureas as 1091
chalcones as 1087
chelerythrine as..... 1090
chelidonine as..... 1090
chloroethylurea (CEU) as 1092
colchicine/analogues 1083
colchicine binding site as..... 1083
combretastatins as 1085
curacin A as 1088
diethylstilbsterol as 1089
5,6-dihydroindolo[2,1-A]isoquinoline derivatives as..... 1091
flavonols as..... 1086
indanosine as..... 1092
LY290181 as..... 1092
nocodazole as 1092
paclitaxel site binding drugs (MT depolymerization inhibitors) as 1079
phenyl-4-quinolones (PQ) as 1090
podophyllotoxin/analogues as..... 1084
quinolones/derivatives as..... 1090
rotenone as..... 1090
RPR112378 as 1093
RPR115781 as 1093
sanguinarine as 1090
steganacin as 1088
sulfonamides as 1089
1,2,3,4-tetrahydro-2-phenyl-quinones as 1090
tricyclic pyron anlog (TP) as 1093
vindesine as 1094
- Multiple linear regression analysis 167
water solubility QSPR Models generated by 167
- Mycophenolate sodium..... 1118
synthesis of..... 1118
- Mycophenolic acid 741
immunosuppressive action of 741
influence on *i*NOS-mediated NO production 741
in autoimmunity therapy 74
modulation of NO production 742

- Neurodegeneration.....157
 caspase enzyme in 157
- Neuronal tracer-toxins592
- Neuropeptide-toxin conjugates.....585
 of immunotoxins585
- Neuroscience research.....588
 immunotoxins in588
- Neurotransmitter835
 glutamine as.....835
- Neutrophil adhesion851
 effects of medium-chain triglycerides (MCT) on.....851
- Neutrophil function.....850
 effects of medium-chain triglycerides (MCT) on.....850
- New drugs.....207,1105
 adefovir dipivoxil (hepseraTM) as207
 alfuzosin hydrochloride (uroxatralTM) as1105
 amrubicin hydrochloride (calsed) as207
 aprepitant (emendTM) as1105
 aripiprazole (abilifyTM) as207
 atomoxetine (stratteraTM) as1109
 atzanavir sulfate (reyatezTM) as.....1108
 azelnidipine (calblockTM) as1110
 bortezomib (velcadeTM) as1110
 dexmethylphenidate hydrochloride (focalinTM) as210
 dutasteride (avodartTM) as212
 emtricitabine (emtrivaTM) as.....1111
 epinastine (alesionTM) as1113
 ertapenem sodium (invarezTM) as212
 escitalopram oxalate (ciprallex[®]) as.....213
 etoricoxib (arcoxiaTM) as213
 everolimus (certicanTM) as1113
 ezetimibe (zetia) as214
 fondaparinux sodium (arixtraTM) as215
 fosfluconazole (proffTM) as.....1115
 fosamprenavir calcium (lexivaTM) as1114
 frovatriptan succinate (frovaTM) as218
 fulvestrant (faslodex[®]) as218
 gefitinib (iressa) as218
 gemifloxacin (zymarTM) as.....1116
 ibandronate (bonivaTM) as.....1117
 lumiracoxib (prexigeTM) as1117
 memantine HCl (namendaTM) as.....1118
 miglustat (zavescaTM) as.....1119
 mycophenolate sodium (myforticTM) as.....1119
 palonosetron (aloxiTM) as1119
 pitavastatin calcium (livaloTM) as.....1120
 rupatadine fumarate (rupafinTM) as.....1121
 sertaconazole (dermofixTM, ertaczoTM) as.....1122
 structure of.....1107
 synthetic approaches to.....207,211
 tadalafil (cialisTM) as1123
 vardenafil (levitraTM) as.....1123
- Nitric oxide741
 in immunity741
- Nitrogen-containing bisphosphonate711
 at cellular level715
 at molecular level713
 at tissue level717
 mechanism of action of711
- pharmacokinetics of712
 structure of712
 toxicology of717
- Non nucleoside HIV reverse transcriptase.....194
 sulfonamide derivatives as194
- Non-imidazole histamine H₃ antagonists.....979
 based other pharmacophores986
 based on 2-aminoethylbenzofurans.....987
 biological properties of.....979
 medicinal chemistry properties of.....979
 SAR of981
 structures of980
 therapeutic utility of988
- Nuclear magnetic resonance (NMR) spectroscopy.....304
 of protein kinase inhibitors304
- Nucleoside analogs affinity361
 for nucleoside diphosphate kinase (NDK).....361
- Nucleoside diphosphate kinase (NDK)361
 active site of.....363
 affinity of nucleotide analogs for.....366
 antiviral drug analogs of.....368
 natural substrates of.....364
 nucleoside analogs phosphorylation by.....361
 sequences of.....361
 structure of.....363
- Nucleoside phosphoramidates.....417
 animal studies of.....417
 cellular uptake of.....417
 pharmacokinetics of.....417
- Omega-3 fatty acids (ω -3 PUFAs)859
 cellular mechanisms of.....859
 food naturally containing of863
 health benefits of.....859
 in cytosol-linked apoptosis864
 in diet.....859
 in mitochondria-linked apoptosis867
 mode of action of.....862
 supplementation of.....860
 therapeutic use of864
- Osteoporosis.....885
 genistein in885
- Oxacephems.....105
 as β -lactams105
- Palonosetron1119
 synthesis of.....1119
- Parkinson's disease (PD)157
 caspase enzyme in157
- Partial least squares method.....167
 water solubility QSPR Models generated by167
- Peptide ligand toxins.....588
- Pharmacokinetic parameters43
 of vanadyl compounds43

- Pheromone biosynthetic enzymes..... 760
 acetyl cholinesterase as 760
 cysteine proteinase inhibitors as 763
 esterases as 760
 juvenile hormone epoxide hydrolases as 762
 juvenile hormone esterase as 761
 oxidoreductases as 762
 proteases as 762
 Pheromone-degrading enzymes 757
 for pest control 757
 in biorational approaches 757
 oxidases as 759
 pheromone esterases as 757
 Philadelphia chromosome..... 285
 in chronic myelogenous leukemia..... 285
 Phosphoproteomics 313
 chemical modification enrichment strategies for ..313,314
 enrichment and MS-based strategies for..... 315
 immobilized metal affinity chromatography of..... 313
 mass spectrometric characterization of 315
 MS ionization/instrumentation in..... 315
 phosphorylated species in 316,317
 phosphospecific antibodies for..... 314
 profiling cellular signaling networks in 319
 stoichiometry of..... 318
 Phosphoramidase activity..... 414
 biological evidence for 416
 chemical evidence for..... 414
 Phosphospecific antibodies 314
 for phosphoproteomics 314
 Phthalide derivative..... 203
 as anti-*helicobacter pylori*..... 203
 Physicochemical descriptors..... 1041
 in property-based drug design 1041
 intestinal absorption to..... 1046
 lipophilicity to 1041
 oral bioavailability to..... 1049
 water solubility to..... 1043
 Pitavastatin calcium 1120
 synthesis of..... 1120
 Plant viruses..... 530
 pokeweed antiviral protein (PAP) for 530
 Platinum complexes 24
 in trypanosomiasis 24
 Pokeweed..... 526
 as antiviral proteins 526
 Pokeweed antiviral protein (PAP) 527
 for cytomegalovirus 527
 for fungal viruses 530
 for herpes simplex virus 527
 for human immunodeficiency virus (HIV)..... 528
 for influenza virus 527
 for poliovirus 527
 for plant viruses..... 530
 Poliovirus 527
 pokeweed antiviral protein (PAP) for 527
 Poly(Lysine)..... 179
 biomedical applications of 179,185
 chemical synthesis of..... 180
 microbial synthesis of..... 179,182
 production of..... 180
 structure of..... 179
 Poly- α -glutamic acid..... 179
 applications of..... 183
 as biological adhesives 185
 as drug carrier 183
 biomedical applications of 179
 chemical synthesis of..... 180
 microbial synthesis of..... 179,181
 production of..... 180
 structure of..... 179
 Prebiotics 889
 clinical consequences of..... 895
 colonic pH of 894
 effect on butyrate..... 894
 effects on composition of intestinal microflora..... 894
 other SCFA 894
 pharmacology of 894
 Probiotics..... 889
 and signal transduction..... 891
 antitoxin effects of..... 890
 cellular/physiological effects of..... 889
 cellular recognition of 891
 cytokine responses of..... 891
 definitions of..... 889
 effects on enterocytes 892
 effects on electrolyte transport..... 893
 effects on gastrointestinal motility..... 893
 effects on humoral immunity..... 892
 effects on immune system/cells..... 891
 effects on innate immunity..... 892
 effects in intestinal lumen..... 893
 effects on microorganisms..... 889
 effects on mucus production 892
 intestinal permeability of..... 892
 interactions with mucus..... 893
 pharmacology of 889
 protecting effect against atopic eczema (allergy)..... 892
 Pronucleotide stratagem 409
 chemical properties of 410
 designing of..... 409
 mechanistic studies of..... 412
 synthesis of..... 410
 Prostacylin (PGI₂)/thromboxane A₂ (TXA₂)..... 639
 biosynthesis of 639
 catalytic domains of..... 640
 coordination of 646
 in endoplasmic reticulum membrane..... 639
 molecular modeling of 640
 N-terminal membrane anchor domains of..... 642
 presentation of..... 641
 Protein kinase inhibitors 301
 fragment based screening approaches to 301
 high-throughput X-ray crystallography of..... 307
 lead generation strategies to..... 303
 lead optimization of..... 309

- novel leads for303
 nuclear magnetic resonance (NMR) spectroscopy of ...304
 structure based drug design of307
 virtual screening approaches towards306
 Pyloricidin derivative203
 as anti-*helicobacter pylori*.....203
 Pyrazoles.....204
 as anti-*helicobacter pylori*.....204
 Pyrimidine nucleoside analogues activation341
 by thymidine kinase341
 γ -Pyrone derivative.....203
 as anti-*helicobacter pylori*.....203
 Pyrrolizine derivative.....636
 as dual COX/5-LOX inhibitor636

 Quinazoline compounds267
 as FLT3 TKI inhibitor267

 Radio-pharmacy.....37
 thiosemicarbazones in37
 Receptor protein tyrosine kinases (RPTKs).....273
 in cancer therapy273
 Rhenium-18862
 biodistribution of.....63
 in treatment of bladder cancer66
 radiochemistry of62
 Rheumatoid arthritis.....155
 caspase enzyme in155
 Ribosome inactivating proteins (RIP).....461,505
 abortifacient activity of.....518
 actions on DNA.....470
 activity of.....461
 activity against viral pathogens.....525
 antiviral activity of.....523
 as immunotoxins540
 axonal retrograde transport of.....519
 biosynthesis of505
 classification of.....487
 complexes of.....483
 cytotoxicity of.....513
 description of461
 distribution of461,462
 entry into cells.....536
 entry into mammalian cells505
 enzymatic activities of.....469
 genetics of487
 gene expression of.....490
 gene structure of.....488
 immunomodulating activity of518
 in bacteria.....461
 in fungi.....461
 in medicine.....523,540
 in plants461
 intracellular routing of.....505
 mediated modulation of host factors537
 membrane disordering activities of470
 molecular evolution of490
 neurotoxicity of519
 non-RIP activities of.....485
 organisation of.....488
 phylogenetic relationship of461,472
 ribosome depurination by523
 structure of.....462,481
 toxicity of.....513,516,518
 Ricin478
 entry into mammalian cells507
 inhibitor design of.....481
 membrane translocation of.....509
 paradigm for cell entry505
 structures of478
 Rupatadine fumarate1121
 synthesis of.....1121
 Ruthenium complexes24
 in trypanosomiasis24
 Rylpiperazine scaffold.....327
 as 5-HT_{2B} antagonist327

 Semicarbazones31
 as anticonvulsants31
 as anti-protozoa agents31
 bioactivity of.....31,32
 metal complexes of.....31
 Sepsis.....156
 caspase enzyme in156
 Serine proteases721
 eukaryotic721
 inhibitors of721
 non-peptide inhibitors of722
 peptide inhibitors of734
 prokaryotic.....721
 Sertaconazole1122
 synthesis of.....1122
 Short chain fatty acids (SCFA).....839
 cellular/physiological effects of.....839
 effects on intestinal dysfunction.....841
 in cancer.....843
 in inflammation.....841
 in thromboresistance.....842
 in vitro studies of.....843
 Solid tumour antigens576
 immunotoxins for576
 Soy flavonoids.....881
 biological activity of.....881
 cellular/physiological effects of.....881
 Spinal cord injury156
 caspase enzyme in156
 STI571289
 effects on autophosphorylation.....289
 effects on cell proliferation.....289
 effects on kinase transphosphorylation.....289
 Stroke.....155
 caspase enzyme in155

- Structure based drug design307
of protein kinase inhibitors307
- Structure-based drug design235
chemogenomics in.....235
- Sugar containing agents441
antibacterial.....441
antiviral activities of.....446
- Sulfonamide derivatives189
antiviral.....189
as herpes virus proteases (HCMV,HSV) inhibitors193
as HIV entry inhibitors.....198
as HIV integrase inhibitors.....195
as HIV protease inhibitors.....190
as non nucleoside HIV reverse transcriptase
inhibitors194
interacting with viral zinc finger proteins.....197
- Sulfonamides628,629
carbonic anhydrases inhibition by.....628,629
- Synthesis805
of fullerence-containing amino acids805
- Synthetic accessibility681
chemistry-based estimation of.....685
complexity-based estimation of.....684
computational estimation of.....684
manual estimation of683
predicting681
retrosynthesis-based estimation of688
- Synthetic approaches1105
to new drugs1105
- Tachykinin (NK₂) receptor antagonists331
dual antagonists NK₁/NK₂ as335
dual antagonists NK₂/NK₃ as337
modelling of338
mutational studies of338
NK₂ selective331,332
triple antagonists NK₁/NK₂/NK₃ as338
- Tadalafil.....1122
synthesis of.....1122
- Thiosemicarbazones.....32,36
antimicrobial activity of32
antitumoral activity of.....33
antiviral activity of.....36
bioactivity of.....31,32
in radio-pharmacy.....37
metal complexes of.....32,37
- Thromboresistance842
short chain fatty acids (SCFC) in.....842
- Thromboxane modulators649
combined.....654
pharmacological properties of654
- Thromboxane receptor antagonists.....652
non-prostanoid.....653
prostanoid.....652
- Thromboxane receptors651
modulators of.....651
- Thromboxane synthase.....650
inhibitors of.....650
modulators of.....650
- Thymidine analogs.....353
conformationally-locked355
sugar-modified.....353
- Thymidine kinase341
cytocolic.....341
mitochondrial342
of herpes simplex-1342
pyrimidine nucleoside analogues activation by.....341
structures of343
substrate activity relationship of.....343
- Titanocene dichloride.....50
as anticancer titanium compound.....50
- Toxicity513,516,518
of ribosome inactivating proteins (RIP).....513,516,518
- Trace elements supplementation.....1
of chromium5
of cobalt.....6
of copper3
of iron.....2
of magnesium.....5
of manganese.....6
of selenium.....5
of zinc.....4
- Transition state analogues.....699
of heparanase.....699
- Traumatic brain injury156
caspase enzyme in156
- Trojan horses383
lock-in *cyclosal*-pronucleotides as383
- Trypanosomatids144
experimental studies on.....144
- Trypanosomiasis.....23
metal complexes in.....25
platinum complexes in.....24
ruthenium complexes in24
- Tetrahydro- β -carbolines328
as 5-HT_{2B} antagonist328
- Tuberculosis438
bioactive carbohydrates in.....438
- Tumor angiogenesis277
kinase inhibitors of.....277
- Tumour metastasis693
heparanase in.....693
- Type 1 dehydroquinase747,755
inhibition of748
inhibitors of747
mechanism of747
- Type 2 diabetes therapy.....897
as small molecule regulators of potential targets of....897
and gluconeogenesis897
and glycogenolysis.....901
AMP allosteric site inhibitors in.....902

- blockade of liver glucocorticoid action as target for....897
 catalytic site inhibitors in901
 fructose-1,6-bisphosphatase (F16BPase) inhibition as
 target for.....900
 glucocorticoid receptor (GR) antagonism
 as target for.....898
 glycogen phosphorylase (GP) inhibition as target for...901
 glucose-6-phosphatase (G6Pase) inhibition
 intervention of hepatic glucose production897
 glycogen synthase kinase-3 (GSK-3) inhibitor in.....903
 glucagon receptor (GlucR) antagonism as target for...904
 G6Pase catalytic enzyme inhibition as target for.....905
 G6P translocase inhibition as target for905
 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD)
 inhibition as target for.....899
 new allosteric site inhibitors in.....902
 as target for904
- Type II dehydroquinase 747
 inhibition of 748
 inhibitors of 747,755
 mechanism of 747
- Tyrosine kinases256
 in human cancers.....257
 strategies to inhibit.....256
- Vanadyl compounds 41
 chemical structure of..... 42
 gastrointestinal absorption features of..... 44
 pharmacokinetic parameters of 43
- Vardenafil..... 1123
 synthesis of..... 1123
- Vascular endothelial growth factor (VEGF).....277
 kinase inhibitors of.....277
- Viral pathogens525
 ribosome inactivating proteins (RIP) against525
- Viral zinc finger proteins.....197
 sulfonamide derivatives interacting with.....197
- Virtual screening.....779,1037,1053
 against HSP90..... 788
- building/fast enumeration of virtual libraries 1054
 computational techniques in..... 1037
 database screening applications in..... 1058
 enrichment factors in 783|
 flexible receptor docking in..... 1059
 high performance computing in..... 1061
 informatics/computing infrastructure in 1061
 in structure-based drug discovery 779
 integration of..... 1053
 in drug discovery process..... 1053
in vivo effects by..... 1054
 prediction of drug-likeness by..... 1055
 prediction of intestinal absorption/oral
 bioavailability 1055
 prediction of CNS activity..... 1056
 predictive drug likeness..... 1054
 recent/popular methods for docking in..... 1056
 structure-based- 1056
 scoring function in 1060
 targets selection/gene-families..... 1054
 using experimental data to enhance docking in..... 1059
 validation of 780
- Warhead.....158
 irreversible binding of.....158
 reversible binding of.....158
- Water solubility QSPR Models.....167
 external validation set of.....171
 generated by artificial neural network methods.....167
 generated by multiple linear regression analysis167
 generated by partial least squares method.....167
 molecular descriptors for.....171
 physico-chemical properties of.....168
 predictive ability of167
 validation of.....173
- Wound healing.....828
 role of arginine in.....828

Copyright of Mini Reviews in Medicinal Chemistry is the property of Bentham Science Publishers Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.